These novel medications , Semaglutide , represent a groundbreaking advancement in managing obesity and potentially related conditions . They are classified as GLP-1 receptor agonists , indicating these https://deaconolih631166.blog-kids.com/41780482/retatrutide-a-thorough-dive-into-metabolic-agents